BRIDION
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BRIDION (BRIDION).
Selective relaxant binding agent; forms complexes with neuromuscular blocking agents (e.g., rocuronium, vecuronium) in plasma, reducing their concentration at the neuromuscular junction.
| Metabolism | Not metabolized; primarily eliminated unchanged in urine. |
| Excretion | Primarily renal excretion of unchanged drug (70-80%) via glomerular filtration; biliary/fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 4-10 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Low protein binding (<10%), primarily to albumin. |
| Volume of Distribution | Volume of distribution at steady state: 0.18-0.22 L/kg, indicating primarily distribution in extracellular fluid. |
| Bioavailability | Intravenous only; bioavailability is 100% IV. |
| Onset of Action | Intravenous: 2-3 minutes (time to reversal of neuromuscular blockade with sugammadex). |
| Duration of Action | Duration of reversal effect: 30-60 minutes for moderate blockade (TOF T2 reappearance); up to 2 hours for deep blockade (PTC 1-2). |
4 mg/kg intravenous bolus for routine reversal of moderate neuromuscular blockade; repeat dose of 4 mg/kg if inadequate response. For deep blockade, 16 mg/kg intravenous bolus.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (GFR 30-89 mL/min). For severe renal impairment (GFR <30 mL/min), use with caution; no specific dose reduction recommended, but prolonged effect may occur. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). For severe hepatic impairment (Child-Pugh C), use with caution due to potential prolonged effect; no specific dose reduction established. |
| Pediatric use | Children and adolescents (2 to 17 years): 4 mg/kg intravenous bolus for routine reversal. For deep blockade, 16 mg/kg intravenous bolus. Infants (28 days to <2 years): 4 mg/kg intravenous bolus for routine reversal; 16 mg/kg for deep blockade. Neonates (<28 days): Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; however, elderly patients may have reduced renal function and increased sensitivity. Use standard dosing with monitoring for prolonged reversal. For patients ≥65 years, consider lower end of dosing range and reassess need for repeat doses. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BRIDION (BRIDION).
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not available. Due to high molecular weight and protein binding, excretion likely low. Use with caution in breastfeeding women. |
| Teratogenic Risk | Insufficient human data. In animal studies, no teratogenic effects observed up to 10x MRHD. FDA Category B. For all trimesters, risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to sugammadex or any component"]
| Precautions | ["Risk of bradycardia and hypotension; monitor hemodynamics","Risk of anaphylactic reactions","Risk of neuromuscular blockade recurrence if inadequate dosing","Not recommended in patients with severe renal impairment (CrCl <30 mL/min)"] |
| Food/Dietary | None known. Bridion is administered intravenously and does not interact with food. However, patients should follow standard preoperative fasting guidelines as directed by their healthcare provider. |
| Clinical Pearls |
Loading safety data…
| Monitor maternal heart rate, blood pressure, and oxygen saturation continuously during use. Fetal heart rate monitoring recommended if used during delivery due to potential for prolonged neuromuscular blockade. |
| Fertility Effects | No adverse effects on fertility observed in animal studies. Human data absent. |
| Administer only as a single bolus dose of 4 mg/kg for routine reversal of rocuronium or vecuronium-induced moderate neuromuscular blockade. For rescue reversal immediately after an intubating dose of rocuronium (1.2 mg/kg), use 16 mg/kg. Do not exceed recommended dose as higher doses may cause vagolytic effects. Contraindicated in patients with known hypersensitivity to sugammadex. Monitor for residual paralysis with quantitative neuromuscular monitoring. Use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for prolonged exposure. Hypersensitivity reactions, including anaphylaxis, have been reported; observe for at least 5 minutes after administration. Recurrence of neuromuscular block is rare but can occur if inadequate reversal; re-dose if necessary. Sugammadex can bind to other drugs, including toremifene, oral contraceptives, and hormonal contraceptives; consider temporary alternative contraception. For patients on anticoagulants, sugammadex may reduce efficacy of heparin and low molecular weight heparins; monitor for bleeding. |
| Patient Advice | Bridion is used to reverse the effects of muscle relaxants given during surgery to help you breathe on your own again. · Tell your doctor if you have kidney problems, as the dose may need adjustment. · Inform your healthcare provider if you are taking any hormonal contraceptives; an alternative non-hormonal contraceptive method should be used for 7 days after receiving Bridion. · You may experience a temporary change in taste or mild nausea after administration. · Serious allergic reactions have occurred; seek immediate medical attention if you develop difficulty breathing, rash, or swelling of the face/throat after receiving Bridion. |